These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 2477931)
1. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience. Drago JR; Badalament RA; Wientjes MG; Smith JJ; Nesbitt JA; York JP; Ashton JJ; Neff JC Urology; 1989 Oct; 34(4):187-92. PubMed ID: 2477931 [TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609 [TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer. Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860 [TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. Oesterling JE J Urol; 1991 May; 145(5):907-23. PubMed ID: 1707989 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. Seamonds B; Yang N; Anderson K; Whitaker B; Shaw LM; Bollinger JR Urology; 1986 Dec; 28(6):472-9. PubMed ID: 2431533 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate. Barak M; Mecz Y; Lurie A; Gruener N J Lab Clin Med; 1989 May; 113(5):598-603. PubMed ID: 2469756 [TBL] [Abstract][Full Text] [Related]
7. Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma. Huang CL; Brassil D; Rozzell M; Schellhammer PF; Wright GL Prostate; 1993; 23(3):201-12. PubMed ID: 7694265 [TBL] [Abstract][Full Text] [Related]
8. Comparison of prostate-specific antigen and prostatic acid phosphatase in the management of prostatic cancer. Turkes A; Nott J; Turkes AO; Griffiths K Am J Clin Oncol; 1988; 11 Suppl 2():S77-9. PubMed ID: 2468280 [TBL] [Abstract][Full Text] [Related]
9. Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer. Mannini D; Maver P; Aiello E; Corrado G; Vecchi F; Bellanova B; Marengo M Urol Res; 1988; 16(1):9-12. PubMed ID: 2449758 [TBL] [Abstract][Full Text] [Related]
10. [Determination of tumor markers in the diagnosis of prostatic cancer]. Casas Terrón E; Mari Ruiz M; Molina Andreu E Arch Esp Urol; 1993 Mar; 46(2):99-103. PubMed ID: 7684585 [TBL] [Abstract][Full Text] [Related]
11. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice. Csapo Z; Brand K; Walther R; Fokas K J Urol; 1988 Nov; 140(5):1032-8. PubMed ID: 2459419 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia. Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815 [TBL] [Abstract][Full Text] [Related]
13. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate]. Morote Robles J; de Torres Mateos JA Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148 [TBL] [Abstract][Full Text] [Related]
14. Serum PSA and PAP measurements discriminating patients with prostate carcinoma from patients with nodular hyperplasia. Shih WJ; Collins J; Mitchell B; Wierzbinski B J Natl Med Assoc; 1994 Sep; 86(9):667-70. PubMed ID: 7525979 [TBL] [Abstract][Full Text] [Related]
15. Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer? Omacini S; Mione R; Barichello M; Santucci Delli Ponti U; Bolgan A; Contemori GP; Petracco S; Capitanio G; Donisi PM; Gion M Eur Urol; 1992; 21 Suppl 1():108-10. PubMed ID: 1385128 [TBL] [Abstract][Full Text] [Related]
16. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease. Buamah PK; Johnson P; Skillen AW Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396 [TBL] [Abstract][Full Text] [Related]
17. A comparative study on the diagnostic value of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients with carcinoma of the prostate gland. van Dieijen-Visser MP; Delaere KP; Gijzen AH; Brombacher PJ Clin Chim Acta; 1988 May; 174(2):131-40. PubMed ID: 2454767 [TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen (PSA) in the management of 500 prostatic patients. Guillet J; Role C; Duc AT; François H Am J Clin Oncol; 1988; 11 Suppl 2():S61-2. PubMed ID: 2468274 [TBL] [Abstract][Full Text] [Related]
19. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240 [TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen as a marker of adenocarcinoma of prostate. Kellokumpu-Lehtinen P; Nurmi M; Koskinen P; Irjala K Urol Res; 1989; 17(4):245-9. PubMed ID: 2475959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]